ChiCTR1800019041: Phase 3 Efficacy and Safety Study of ACC007 Combined with 3TC+TDF in the Treatment of HIV/AIDS |
|
|
| Completed | 3 | 630 | | Oral administration, once a day, ACC007 150mg + EFV placebo 1 tablet + 3TC 300mg + TDF 300mg. Blinding treatment period: Week 0 to Week 48; Open treatment period: Week 48 to Week 96 ;Oral administration, once a day, EFV 600mg + ACC007 placebo 1 tablet + 3TC 300mg + TDF 300mg. Blinding treatment period : Week 0 to Week 48; Open treatment period: Week 48 to Week 96 | Beijing You An Hospital, Capital Medical University; Jiangsu Aidea Pharmaceutical Co., Ltd, Self-financing | Non-nucleoside reverse transcriptase inhibitors,and other antiretroviral drugs in combination with HIV/AIDS | | | | |
ChiCTR2100051605: Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate Switching From a Regimen of Two Nucleoside Reverse Transcriptase Inhibitors (NRTI) Plus a Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) to a Fixed Dose Combination(FDC) of ACC007 Versus Elvitegravir, in Virologically-Suppressed, HIV-1 Infected Participants&# |
|
|
| Recruiting | 3 | 762 | | Tablet; Specification: Each tablet contains 150 mg of ACC007, 300 mg of lamivudine and 300 mg of tenofovir fumarate; it is orally administered on an empty stomach every day ;Tablet; Specification: Each tablet contains 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine and 10mg of tenofovir alafenamide fumarate; it is orally administered with food every day | Beijing Ditan Hospital, Capital Medical University; Nanjing Accelas Pharmaceutical Co., Ltd. and Jiangsu Aidea Pharmaceutical Co., Ltd., self-funded | HIV/AIDS | | | | |
